Jasper Therapeutics (NASDAQ:JSPR) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Piper Sandler initiated coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price objective for the company. Finally, William Blair began coverage on Jasper Therapeutics in a research report on Wednesday, October 14th. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.33.

Jasper Therapeutics Trading Down 2.2%

NASDAQ JSPR opened at $0.52 on Friday. The company has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $0.86. The company has a market cap of $17.31 million, a P/E ratio of -0.33 and a beta of 3.16. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $2.42.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. Sell-side analysts predict that Jasper Therapeutics will post -0.94 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.